Suchergebnisse - "Shi, Yuankai"

PubPharm (531)

11

Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer : a phase Ⅱ study

enthalten in: EBioMedicine | 2024

von Yang, L. | Zhang, W. | Fan, N. | +24

12

Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era : a multi-institutional cohort study

enthalten in: Annals of hematology | 2024

von Zhong, Q. | Chen, H. | Chen, D. | +11

13

Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC : A Multicenter, Open-Label, Single-Arm, Phase 1/2 Study

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2024

von Shi, Y. | Hu, X. | Li, X. | +15

14

Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC : Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE)

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2024

von Shi, Y. | Chen, J. | Yang, R. | +22

15

Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma : 5-year follow-up results of the phase 3 HLX01-NHL03 study

enthalten in: BMC cancer | 2024

von Qin, Y. | Song, Y. | Wang, D. | +25

16

Integrative analyses of bulk, single-cell and spatial transcriptomics identified diabetes mellitus-related signature as a prognostic factor in pancreatic adenocarcinoma

enthalten in: ResearchSquare.com | 2023

von Tang, L. | Xie, T. | Fan, G. | +3

17

China Anti-Cancer Association (CACA) guidelines for holistic integrative management of lymphoma (version 2022)

enthalten in: Holistic integrative oncology | 2023

von Zhang, Q. | Feng, J. | Wang, H. | +24

18

An immunosuppressive subtype of senescent tumor cells predicted worse immunotherapy response in lung adenocarcinoma

enthalten in: iScience | 2023

von Fan, G. | Xie, T. | Tan, Q. | +4

19

Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study

enthalten in: Annals of hematology | 2023

von Zhong, Q. | Chen, H. | Chen, D. | +11

20

Identification of an antigen-presenting cells/T/NK cells-related gene signature to predict prognosis and CTSL to predict immunotherapeutic response for lung adenocarcinoma : an integrated analysis of bulk and single-cell RNA sequencing

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Huang, L. | Lou, N. | Xie, T. | +3